METHOD OF INDIVIDUAL THERAPY RESULT FORECAST FOR LOCALLY ADVANCED MALIGNANT TUMOUR OF OROPHARYNGEAL AREA Russian patent published in 2009 - IPC G01N33/52 A61B10/00 

FIELD: medicine.

SUBSTANCE: in first version malonic dialdehyde (MDA) content is defined in patient blood plasma before the beginning of treatment. Then forecast is implemented: if MDA is under 5 optic density units, then favourable treatment result is forecast, meaning that full-scale treatment can be performed, tumour and regional metastasis regress can be over 75%, and time to disease advance can take over 12 months. If MDA is within 5 to 8 optic density units, then satisfactory treatment course is forecast, meaning that local disease advance is expected in 12 months time or less from the treatment beginning. If MDA is over 8 optic density units, that unfavourable treatment course is forecast, meaning the absence of complete remission, continued tumour growth despite treatment, death caused by malignant tumour within one year, median survival of 6 months. In second version before the beginning of treatment, maximum chemiluminescence intensity (Imax) is defined in patient blood plasma, followed by malonic dialdehyde (MDA) content determination in blood plasma. Then Imax/MDA index is calculated, and forecast is implemented: if Imax/MDA is over 0.35, then favourable treatment result is forecast, meaning that full-scale treatment can be performed, tumour and regional metastasis regress can be over 75%, and time to disease advance can take over 12 months. If Imax/MDA is within 0.25 to 0.35, then satisfactory treatment course is forecast, meaning that local disease advance is expected in 12 months time or less from the treatment beginning. If Imax/MDA is under 0.25, that unfavourable treatment course is forecast, meaning the absence of complete remission, continued tumour growth despite treatment, death caused by malignant tumour within one year, median survival of 6 months.

EFFECT: first possibility of individual result forecast before the beginning of treatment for locally advanced malignant tumours of oropharyngeal area for any initial tumour volume and disease stage.

2 cl, 1 tbl, 3 ex